FDA’s latest whitepaper shows how scalable quality management investments in pharma reduce costs, improve reliability, and ...

Re-Vana’s drug delivery technology is designed to release treatments over a 6- to 12-month period, with the goal of reducing ...

The two companies have entered into an agreement to develop respiratory, immunology, inflammation, and cancer therapies.

EMA encourages NAMs to replace animal testing, aligning with 3Rs principles, and has published a concept paper on regulatory ...

Many companies face FDA complete response letters due to ongoing chemistry, manufacturing, and controls, or CMC, and ...

While a one-stop shop still has its advantages, sponsor companies and CDMOs are starting to see each other not as ...

The agency has given a positive recommendation for a change in the gas propellant in Trixeo Aerosphere and Riltrava ...

Addressing human interventions to reduce their impact on contamination requires addressing broader considerations than ...

Pharmaceutical Technology serves as the connection to bio manufacturing and development, featuring regulatory updates and ...

In this exclusive Drug Digest video, Deepak Bahl from Roquette and Jagruti Patel from Lonza look at strategies for ...

In this episode of the Ask the Expert video series, Susan J. Schniepp, distinguished fellow at Regulatory Compliance ...

Cross-functional trade compliance planning is critical as pharma braces for broad 232 tariffs and shifting United States-China-India supply dynamics.